4.7 Article

Nef Decreases HIV-1 Sensitivity to Neutralizing Antibodies that Target the Membrane-proximal External Region of TMgp41

期刊

PLOS PATHOGENS
卷 7, 期 12, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.ppat.1002442

关键词

-

资金

  1. European Commission [237265]
  2. NIAID NIH [AI077412, RO1AI59159]
  3. Swiss National Science Foundation [3100A0-128655]

向作者/读者索取更多资源

Primate lentivirus nef is required for sustained virus replication in vivo and accelerated progression to AIDS. While exploring the mechanism by which Nef increases the infectivity of cell-free virions, we investigated a functional link between Nef and Env. Since we failed to detect an effect of Nef on the quantity of virion-associated Env, we searched for qualitative changes by examining whether Nef alters HIV-1 sensitivity to agents that target distinct features of Env. Nef conferred as much as 50-fold resistance to 2F5 and 4E10, two potent neutralizing monoclonal antibodies (nAbs) that target the membrane proximal external region (MPER) of TMgp41. In contrast, Nef had no effect on HIV-1 neutralization by MPER-specific nAb Z13e1, by the peptide inhibitor T20, nor by a panel of nAbs and other reagents targeting gp120. Resistance to neutralization by 2F5 and 4E10 was observed with Nef from a diverse range of HIV-1 and SIV isolates, as well as with HIV-1 virions bearing Env from CCR5-and CXCR4-tropic viruses, clade B and C viruses, or primary isolates. Functional analysis of a panel of Nef mutants revealed that this activity requires Nef myristoylation but that it is genetically separable from other Nef functions such as the ability to enhance virus infectivity and to downregulate CD4. Glycosylated-Gag from MoMLV substituted for Nef in conferring resistance to 2F5 and 4E10, indicating that this activity is conserved in a retrovirus that does not encode Nef. Given the reported membrane-dependence of MPER-recognition by 2F5 and 4E10, in contrast to the membrane-independence of Z13e1, the data here is consistent with a model in which Nef alters MPER recognition in the context of the virion membrane. Indeed, Nef and Glycosylated-Gag decreased the efficiency of virion capture by 2F5 and 4E10, but not by other nAbs. These studies demonstrate that Nef protects lentiviruses from one of the most broadly-acting classes of neutralizing antibodies. This newly discovered activity for Nef has important implications for anti-HIV-1 immunity and AIDS pathogenesis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Multidisciplinary Sciences

Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness

Fritz Obermeyer, Martin Jankowiak, Nikolaos Barkas, Stephen F. Schaffner, Jesse D. Pyle, Leonid Yurkovetskiy, Matteo Bosso, Daniel J. Park, Mehrtash Babadi, Bronwyn L. MacInnis, Jeremy Luban, Pardis C. Sabeti, Jacob E. Lemieux

Summary: This study developed a model called PyR0 for rapid detection and characterization of new SARS-CoV-2 lineages, and identified mutations relevant to fitness. By applying PyR0 to all publicly available SARS-CoV-2 genomes, the researchers discovered mutations that increase fitness and predicted the growth of new lineages based on their mutational profile. The model also prioritizes mutations of biological and public health concern for further study.

SCIENCE (2022)

Article Biology

Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection

Noah J. Silverstein, Yetao Wang, Zachary Manickas-Hill, Claudia Carbone, Ann Dauphin, Brittany P. Boribong, Maggie Loiselle, Jameson Davis, Maureen M. Leonard, Leticia Kuri-Cervantes, Nuala J. Meyer, Michael R. Betts, Jonathan Z. Li, Bruce D. Walker, Xu G. Yu, Lael M. Yonker, Jeremy Luban

Summary: This study suggests that the abundance of specific lymphoid cell types is associated with the severity and recovery of COVID-19. Innate lymphoid cells (ILCs) decrease in number with age and in males, and their decreased abundance is seen in COVID-19 patients and children with MIS-C. However, the numbers of ILCs gradually recover in children with MIS-C. These results indicate that the abundance of lymphoid cell subsets plays a significant role in COVID-19 severity and recovery, potentially contributing to disease tolerance and tissue homeostasis.
Article Microbiology

Increased Prevalence of Lassa Fever Virus-Positive Rodents and Diversity of Infected Species Found during Human Lassa Fever Epidemics in Nigeria

Anise N. Happi, Testimony J. Olumade, Olusola A. Ogunsanya, Ayotunde E. Sijuwola, Seto C. Ogunleye, Judith U. Oguzie, Cecilia Nwofoke, Chinedu A. Ugwu, Samuel J. Okoro, Patricia I. Otuh, Louis N. Ngele, Oluwafemi O. Ojo, Ademola Adelabu, Roseline F. Adeleye, Nicholas E. Oyejide, Clinton S. Njaka, Jonathan L. Heeney, Christian T. Happi

Summary: In Lassa fever endemic areas of Nigeria, the prevalence of Lassa virus is high in different species of rodents, indicating complex transmission dynamics and increased environmental contact in reservoirs. This has direct implications for understanding the transmission risk, mitigation, and prevention of Lassa fever in humans.

MICROBIOLOGY SPECTRUM (2022)

Article Infectious Diseases

Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study

Ana Atti, Ferdinando Insalata, Edward J. Carr, Ashley D. Otter, Javier Castillo-Olivares, Mary Wu, Ruth Harvey, Michael Howell, Andrew Chan, Jonathan Lyall, Nigel Temperton, Diego Cantoni, Kelly da Costa, Angalee Nadesalingam, Andrew Taylor-Kerr, Nipunadi Hettiarachchi, Caio Tranquillini, Jacqueline Hewson, Michelle J. Cole, Sarah Foulkes, Katie Munro, Edward J. M. Monk, Iain D. Milligan, Ezra Linley, Meera A. Chand, Colin S. Brown, Jasmin Islam, Amanda Semper, Andre Charlett, Jonathan L. Heeney, Rupert Beale, Maria Zambon, Susan Hopkins, Tim Brooks, Victoria Hall

Summary: This study investigated the serological differences between SARS-CoV-2 reinfection cases and controls, and identified antibody correlates of protection against reinfection. The results showed that before vaccination, protection against reinfection was directly correlated with anti-S levels, PV-N and LV-N titres, but not with anti-N levels.

JOURNAL OF INFECTION (2022)

Article Immunology

Influenza A (N1-N9) and Influenza B (B/Victoria and B/Yamagata) Neuraminidase Pseudotypes as Tools for Pandemic Preparedness and Improved Influenza Vaccine Design

Kelly A. S. da Costa, Joanne Marie M. Del Rosario, Matteo Ferrari, Sneha Vishwanath, Benedikt Asbach, Rebecca Kinsley, Ralf Wagner, Jonathan L. Heeney, George W. Carnell, Nigel J. Temperton

Summary: By using NA pseudoviruses and developing the pELLA assay, we successfully measured neuraminidase inhibition levels in different influenza sera and found that pELLA is more sensitive than the commercially available NA-Fluor(TM). These studies may lead to the design of more potent, longer-lasting, and broader protective vaccines that can be used in a pre-pandemic approach in combination with HA vaccines.

VACCINES (2022)

Editorial Material Infectious Diseases

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies

Angalee Nadesalingam, Diego Cantoni, Ernest T. Aguinam, Andrew C. Y. Chan, Minna Paloniemi, Luis Ohlendorf, Charlotte George, George Carnell, Jon Lyall, Matteo Ferrari, Nigel Temperton, Ralf Wagner, Javier Castillo-Olivares, Helen Baxendale, Jonathan L. Heeney

LANCET MICROBE (2023)

Article Microbiology

AP-2 Adaptor Complex-Dependent Enhancement of HIV-1 Replication by Nef in the Absence of the Nef/AP-2 Targets SERINC5 and CD4

Balaji Olety, Yoshiko Usami, Yuanfei Wu, Paul Peters, Heinrich Gottlinger, Stephen P. Goff

Summary: The HIV-1 Nef protein downregulates the viral receptor CD4 and the antiviral proteins SERINC3 and SERINC5. In the absence of SERINC3 and SERINC5, Nef is no longer required for viral infectivity and replication in Jurkat Tag T cells, but remains crucial for HIV-1 replication in MOLT-3 cells. The Nef-mediated enhancement of HIV-1 replication in MOLT-3 cells is independent of the Nef-interacting kinases LCK and PAK2.
Article Medicine, General & Internal

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

Felicity Liew, Shubha Talwar, Andy Cross, Brian J. Willett, Sam Scott, Nicola Logan, Matthew K. Siggins, Dawid Swieboda, Jasmin K. Sidhu, Claudia Efstathiou, Shona C. Moore, Chris Davis, Noura Mohamed, Jose Nunag, Clara King, A. A. Roger Thompson, Sarah L. Rowland-Jones, Annemarie B. Docherty, James D. Chalmers, Ling-Pei Ho, Alexander Horsley, Betty Raman, Krisnah Poinasamy, Michael Marks, Onn Min Kon, Luke Howard, Daniel G. Wootton, Susanna Dunachie, Jennifer K. Quint, Rachael A. Evans, Louise V. Wain, Sara Fontanella, Thushan I. de Silva, Antonia Ho, Ewen Harrison, J. Kenneth Baillie, Malcolm G. Semple, Christopher Brightling, Ryan S. Thwaites, Lance Turtle, Peter J. M. Openshaw

Summary: This study examined the nasal and plasma antibody responses in COVID-19 hospitalized patients one year after discharge and vaccination. The findings showed sustained elevated antibody responses in both nasal and plasma samples for at least 12 months, but the nasal antibody response was minimally influenced by vaccination. These findings highlight the importance of developing vaccines that enhance nasal immunity.

EBIOMEDICINE (2023)

Review Immunology

A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy

Kristine A. Moore, Tabitha Leighton, Julia T. Ostrowsky, Cory J. Anderson, Richard N. Danila, Angela K. Ulrich, Eve M. Lackritz, Angela J. Mehr, Ralph S. Baric, Norman W. Baylor, Bruce G. Gellin, Jennifer L. Gordon, Florian Krammer, Stanley Perlman, Helen Rees, Melanie Saville, Charlotte L. Weller, Michael T. Osterholm

Summary: Broadly protective coronavirus vaccines are crucial for future protection from SARS-CoV-2 variants and future outbreaks caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap aims to promote their development. It is funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation and involves collaboration with international experts. The roadmap outlines major research areas, milestones, and priorities for funding and research campaigns.

VACCINE (2023)

Article Immunology

Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants

George W. Carnell, Martina Billmeier, Sneha Vishwanath, Maria Suau Sans, Hannah Wein, Charlotte L. George, Patrick Neckermann, Joanne Marie M. Del Rosario, Alexander T. Sampson, Sebastian Einhauser, Ernest T. Aguinam, Matteo Ferrari, Paul Tonks, Angalee Nadesalingam, Anja Schuetz, Chloe Qingzhou Huang, David A. Wells, Minna Paloniemi, Ingo Jordan, Diego Cantoni, David Peterhoff, Benedikt Asbach, Volker Sandig, Nigel Temperton, Rebecca Kinsley, Ralf Wagner, Jonathan L. Heeney

Summary: The rapid development of the first generation COVID-19 vaccines has saved millions of lives and potentially prevented long-term complications from SARS-CoV-2 infection. Successful vaccines have used the full-length SARS-CoV-2 spike protein as an immunogen. However, new variants have emerged, necessitating the development of next generation vaccines that target multiple neutralizing epitopes on the spike protein to provide broad protection against variant strains.

FRONTIERS IN IMMUNOLOGY (2023)

Article Medicine, General & Internal

Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study

Hamish J. C. McAuley, Rachael A. Evans, Charlotte E. Bolton, Christopher E. Brightling, James D. Chalmers, Annemarie B. Docherty, Omer Elneima, Paul L. Greenhaff, Ayushman Gupta, Victoria C. Harris, Ewen M. Harrison, Ling-Pei Ho, Alex Horsley, Linzy Houchen-Wolloff, Caroline J. Jolley, Olivia C. Leavy, Nazir I. Lone, William D. C. Man, Michael Marks, Dhruv Parekh, Krisnah Poinasamy, Jennifer K. Quint, Betty Raman, Matthew Richardson, Ruth M. Saunders, Marco Sereno, Aarti Shikotra, Amisha Singapuri, Sally J. Singh, Michael Steiner, Ai Lyn Tan, Louise Wain, Carly Welch, Julie Whitney, Miles D. Witham, Janet Lord, Neil J. Greening, HOSP-COVID Study Collaborat Grp

Summary: This study recruited COVID-19 survivors in the UK and objectively measured frailty using FFP. The results showed that frailty and pre-frailty are common after hospitalization with COVID-19, and comprehensive assessment and interventions targeting frailty are needed beyond the initial illness.

ECLINICALMEDICINE (2023)

Article Biochemistry & Molecular Biology

Transcriptional and chromatin profiling of human blood innate lymphoid cell subsets sheds light on HIV-1 pathogenesis

Yetao Wang, Lawrence Lifshitz, Noah J. Silverstein, Esther Mintzer, Kevin Luk, Pamela StLouis, Michael A. Brehm, Scot A. Wolfe, Steven G. Deeks, Jeremy Luban

Summary: Innate lymphoid cells (ILCs) are a diverse population of cells that include NK cells and play important roles in tissue homeostasis and repair, inflammation, and protection from infection. This study used transcriptional and chromatin profiling to investigate the interplay between human blood ILCs and their responses to HIV-1 infection. The findings reveal the existence of four main ILC subsets in human blood and provide insights into how HIV-1 infection disrupts NK cells and their homeostatic function.

EMBO JOURNAL (2023)

Article Multidisciplinary Sciences

The HIV-1 capsid core is an opportunistic nuclear import receptor

Guangai Xue, Hyun Jae Yu, Cindy Buffone, Szu-Wei Huang, KyeongEun Lee, Shih Lin Goh, Anna T. T. Gres, Mehmet Hakan Guney, Stefan G. G. Sarafianos, Jeremy Luban, Felipe Diaz-Griffero, Vineet N. N. KewalRamani

Summary: The entry of HIV-1 into the nucleus is regulated by the interaction between the viral capsid protein CA and nuclear pore complex proteins Nup35 and POM121. This interaction is also influenced by soluble host factors such as Cyclophilin A. These findings highlight the role of CA as a macromolecular nuclear transport receptor and provide insights into the mechanism of HIV-1 nuclear invasion.

NATURE COMMUNICATIONS (2023)

Article Engineering, Biomedical

A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses

Sneha Vishwanath, George William Carnell, Matteo Ferrari, Benedikt Asbach, Martina Billmeier, Charlotte George, Maria Suau Sans, Angalee Nadesalingam, Chloe Qingzhou Huang, Minna Paloniemi, Hazel Stewart, Andrew Chan, David Arthur Wells, Patrick Neckermann, David Peterhoff, Sebastian Einhauser, Diego Cantoni, Martin Mayora Neto, Ingo Jordan, Volker Sandig, Paul Tonks, Nigel Temperton, Simon Frost, Katharina Sohr, Maria Teresa Lluesma Ballesteros, Farzad Arbabi, Johannes Geiger, Christian Dohmen, Christian Plank, Rebecca Kinsley, Ralf Wagner, Jonathan Luke Heeney

Summary: A computationally designed antigen based on the spike protein of sarbecoviruses elicits broad humoral responses against severe acute respiratory syndrome viruses in mice, rabbits, and guinea pigs.

NATURE BIOMEDICAL ENGINEERING (2023)

Article Immunology

Immunogenicity and Pre-Clinical Efficacy of an OMV-Based SARS-CoV-2 Vaccine

Alberto Grandi, Michele Tomasi, Irfan Ullah, Cinzia Bertelli, Teresa Vanzo, Silvia Accordini, Assunta Gagliardi, Ilaria Zanella, Mattia Benedet, Riccardo Corbellari, Gabriele Di Lascio, Silvia Tamburini, Elena Caproni, Lorenzo Croia, Micol Rava, Valeria Fumagalli, Pietro Di Lucia, Davide Marotta, Eleonora Sala, Matteo Iannacone, Priti Kumar, Walther Mothes, Pradeep D. Uchil, Peter Cherepanov, Martino Bolognesi, Massimo Pizzato, Guido Grandi

Summary: The study demonstrates that engineered OMVs vaccines can induce effective immune responses, producing neutralizing antibodies and protecting animals from SARS-CoV-2 infection. Furthermore, the vaccine can also elicit immune responses against the Omicron BA.1 and BA.5 variants. OMV-based SARS-CoV-2 vaccines, with the convenience of engineering, production, and distribution, can be a crucial addition to the currently available vaccines.

VACCINES (2023)

暂无数据